Resumen de: US2023030998A1

The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.

Resumen de: US2023031954A1

The present invention is directed to methods of treating hematological cancers, such as acute myleiod leukemia, with tetracyclines, or a pharmaceutically acceptable salt thereof.

Resumen de: WO2023009833A1

Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I), (II), or (III)) and compositions (e.g., pharmaceutical compositions) which inhibit IRAK and/or FLT3 and which can be used for treating, for example, certain diseases. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as hematopoietic cancers, myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), etc.). Additional embodiments provide disease treatment using combinations of the inventive IRAK and/or FLT3 inhibiting compounds with other therapies, such as cancer therapies.

Resumen de: AU2022287584A1

Provided herein are methods of treating acute myeloid leukemia (AML) and multiple myeloma (MM) by administering an effective amount of a cell population comprising natural killer cells, wherein the cell population comprising natural killer cells is produced by a three stage method comprising culturing a population of hematopoietic stem or progenitor cells in media comprising stem cell mobilizing factors, e.g., three-stage methods of producing NK cells in media comprising stem cell mobilizing factors starting with hematopoietic stem or progenitor cells from cells of the placenta, for example, from placental perfusate (e.g., human placental perfusate) or other tissues, for example, umbilical cord blood or peripheral blood. Further provided herein are methods of using the NK cells produced by the three-stage methods provided herein to suppress the proliferation of acute myeloid leukemia cells. In certain embodiments, the NK cells produced by the three-stage methods described herein are used in combination with IL

Resumen de: AU2022287569A1

Provided herein is 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin- 4 yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, and methods for treating, preventing or managing multiple myeloma using such compounds. Also provided are pharmaceutical compositions comprising the compounds, and methods of use of the compositions.

Resumen de: WO2023009434A1

This disclosure relates to methods for treating cancer in a subject identified as having acute myeloid leukemia (AML), comprising administering an anti-ILT3 antigen binding protein, or antigen binding fragment to the patient every three weeks (Q3W).

Resumen de: WO2023005280A1

Disclosed in the present invention are preparation and application of an aminopyrimidine derivative selectively targeting CDK9. Also disclosed in the present invention are a preparation method for the compound and an application of the compound in prevention and/or treatment of tumor-related diseases including glioma, various leukemia, lymphoma, liver cancer, stomach cancer, prostate cancer, ovarian cancer, breast cancer, lung cancer and the like. The compound can effectively and selectively inhibit the activity of CDK9 protein, and meanwhile, the compound shows remarkable anti-tumor activity in cancer cells such as MV4-11, MCF-7 and MOLM-13.

Resumen de: WO2023005281A1

Disclosed are a preparation method for and an application of a novel CDK9 inhibitor having a macrocyclic skeleton structure (I). The compound can effectively inhibit the activity of CDK9 protein and has high selectivity for CDK9. Also disclosed are a preparation method for the compound and an application thereof in preventing and/or treating tumor-related diseases, comprising glioma, various types of leukemia, lymphoma, liver cancer, gastric cancer, prostate cancer, ovarian cancer, breast cancer, lung cancer, etc.

Resumen de: WO2023009982A1

Disclosed are deubiquitinase (DUB) JOSD1 inhibitors and methods of treating a disease or disorder mediated by dysregulated Janus Kinase 2 (JAK2) activity, in a subject in need thereof, comprising administering a therapeutically effective amount of one or more DUB inhibitors.

Resumen de: WO2023004624A1

Provided are a product for detecting an LGALS3BP gene or an LGALS3BP protein and the use thereof in the preparation of a tool for the diagnosis and/or prognosis of myeloma. Further provided are an inhibitor of the LGALS3BP gene or the LGALS3BP protein and the use thereof in the preparation of a drug for the treatment of myeloma.

Resumen de: WO2023004626A1

The present invention relates to the technical fields of molecular biology and biomedicine, and specifically relates to a myeloma biomarker and the use thereof. According to the above-mentioned use of the present invention, whether a subject has myeloma, or whether the subject is at a risk of having myeloma, or whether the prognosis of the subject is good can be judged by means of detecting an expression level of an SERPINF2 gene or an SERPINF2 protein in a subject, thereby guiding a clinician to provide an effective prevention means or treatment regimen for the subject, which is beneficial for improving the survival rate of the subject.

Resumen de: AU2021306808A1

The present invention relates to satraplatin for use in a method of treating a malignancy of the lymphoid tissue in a mammal, preferably a human, and in particular of a malignancy of the lymphoid tissue with primary or secondary central nervous system (CNS) manifestation such as primary diffuse large B cell lymphoma of the CNS.

Resumen de: AU2021297353A1

The present invention provides compositions and methods for the mitigation of side effects of chemotherapy, for example in human subjects with hematologic malignancies (such as lymphoma, leukemia and myelodysplastic syndrome) as well as subjects with other malignancies or other conditions that may be treated with chemotherapy, such as high dose therapy (HOT) or a combination of high dose HDT and a hematopoietic stem cell transplant. The methods comprise administration of endothelial cells, such as engineered human umbilical vein endothelial cells engineered to express the adenoviral E40RF1 protein (E40RF1+ HUVECs), to human subjects. The side effects mitigated by the compositions and methods of the invention include, but are not limited to, oral / gastrointestinal side effects and febrile neutropenia.

Resumen de: WO2023010126A2

Provided herein are chimeric antigen receptors (CARs) with binding specificity for CD123. Nucleic acids, expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs are also disclosed, and methods including the treatment of a hematopoietic malignancy or premalignancy characterized by the expression of CD123, e.g., leukemias such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Resumen de: WO2023010031A1

The present disclosure provides methods of treating a blood cancer, such as multiple myeloma, by administering a heterodimeric protein comprising a first monomer comprising an IL15 protein-Fc domain fusion and a second monomer comprising an IL15Rα protein-Fc domain fusion.

Resumen de: AU2021293006A1

The present invention is directed to a method of treating a hematologic malignancy such as acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), including hematologic malignancies that are refractive to chemotherapeutic and/or hypomethylating agents. The method concerns administering a CD123 x CD3 bispecific binding molecule to a patient in an amount effective to stimulate the killing of cells of said hematologic malignancy in said patient. The present invention is particularly directed to the embodiment of such method in which a cellular sample from the patient prior to such administration evidences an expression of one or more target genes that is increased relative to a baseline level of expression of such genes, for example, a baseline level of expression of such genes in a reference population of individuals who are suffering from the hematologic malignancy, or with respect to the level of expression of a reference gene.

Resumen de: AU2021275055A1

The present invention provides compositions comprising antibodies to interleukin 7 receptor (IL7R), as well methods for treatment using the IL7R antibodies.

Resumen de: AU2021272291A1

Methods of treating cancers using a BCMAxCD3 bispecific antibody are described.

Resumen de: AU2021271971A1

The present application provides compositions and methods for treating cancers, including follicular lymphoma, T cell lymphoma and adenoid cystic carcinoma, using an anti-CD137 antibody that specifically binds to an extracellular domain of human CD137. In some embodiment, combination therapies including the anti-CD137 antibody and an immune checkpoint inhibitor, and/or a chemotherapeutic agent are provided. Biomarkers such as total CD137, membrane bound CD137 (mCD137), soluble CD137 (sCD137), CD137 ligand, Ki67, CD8+ effector memory T (T

Resumen de: US2023031558A1

The disclosure provides Moloney murine leukemia virus (MMLV) reverse transcriptase (RTase) mutants. The disclosure as provides suitable amino acid positions in MMLV RTase for mutagenesis and methods and kits for using MMLV RTase mutants to synthesize cDNA from RNA templates.

Resumen de: AU2022291559A1

Abstract Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.

Resumen de: MD20210046A1

The invention relates to chemistry and medicine, in particular to the use of a copper coordination compound of the class of transition metal thiosemicarbazonates as a human myeloid leukemia HL-60 cells proliferation inhibitor and can be used in medicine in the treatment of leukemia.According to the invention, claimed is the use as a human myeloid leukemia HL-60 cells proliferation inhibitor of chloro-{N-ethyl-N'-[phenyl(pyridin-2-yl)methylidene]carbamohydrazonothioato}copper of the formula:.Said compound expands the arsenal of inhibitors of human myeloid leukemia HL-60 cells with high biological activity.

Resumen de: US2023026111A1

The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TCR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.

Resumen de: WO2023002362A1

This invention relates to therapies useful for the treatment of hematological malignancies. In particular the invention relates to a method of treating acute myeloid leukemia (AML) in a patient in need thereof, wherein said patient is positive for at least one mutation of the FLT3 gene, said method comprising administering to said patient a smoothened inhibitor, or a pharmaceutically acceptable salt thereof, in combination with azacitidine, thereby treating said acute myeloid leukemia. The invention also relates to associated combination therapies, pharmaceutical compositions, pharmaceutical uses and kits.

Resumen de: US2023027088A1

An EP300/CBP inhibitor, specifically provided is a compound as shown in formula I, or a deuterated product thereof, or a salt thereof, or a conformational isomer thereof, or a crystal form thereof, or a solvate thereof. The compound is highly selective for EP300/CBP, and can effectively inhibit the activity of EP300/CBP; in addition, the compound has an excellent inhibitory effect on various tumor cells including prostate cancer cells, leukemia cells, breast cancer cells and multiple myeloma cells. The compound has broad application prospects in the preparation of an EP300/CBP inhibitor, and drugs for preventing and/or treating tumors, myeloid hematopoietic stem/progenitor cells malignant disease, and regulating regulatory T cells.